Immunogenicity of the Pandemrix A (H1N1) 2009 Influenza Vaccine in Hemodialysed and Renal Transplanted Patients
Author Information
Author(s): Anneleen Hombrouck, Broeders N, Labriola L, Abramowicz D, Jadoul M, Goubau P, Van Gucht S, Brochier B, Thomas I
Primary Institution: National Influenza Centre, Communicable and Infectious Diseases, Scientific Institute of Public Health, Brussels
Hypothesis
The immunogenicity of the Pandemrix vaccine is less effective in immunodepressed patients compared to immunocompetent patients.
Conclusion
The study found that only 60% of hemodialysed patients and 44% of renal transplanted patients developed sufficient neutralizing antibody titers after vaccination.
Supporting Evidence
- Thirty out of 32 healthy participants (93%) had at least four-fold increases in SN titers between day 0 and day 30.
- Among dialysed participants, 64 out of 106 (60%) had at least four-fold increases in SN titers.
- Among renal transplanted patients, 49 out of 112 participants (44%) seroconverted between day 0 and day 30.
Takeaway
This study looked at how well a flu vaccine worked for people with kidney issues. It found that not everyone got enough protection from the vaccine.
Methodology
Neutralizing antibodies were measured in sera collected from participants before and after vaccination using a seroneutralisation assay.
Potential Biases
Potential selection bias in recruiting participants from specific hospitals.
Limitations
The study may not represent all immunodepressed patients as it focused on specific groups.
Participant Demographics
The study included 32 healthy volunteers, 106 hemodialysed patients, and 112 renal transplanted patients.
Statistical Information
P-Value
p<0.05
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website